Searching the RRID Resource Information Network
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Joslin Diabetes Center Advanced Genomics and Genetics Core Facility Resource Report Resource Website 500+ mentions |
Joslin Diabetes Center Advanced Genomics and Genetics Core Facility (RRID:SCR_009873) | core facility, access service resource, service resource | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 27,2023. Core that provides services for genetic and genomic analysis, including DNA extraction from blood, access to DNA collections from the Core?s repository, SNP genotyping, and support for gene expression studies based on both high-density oligonucleotide arrays and real-time quantitative PCR. | gene analysis, genome analysis, dna extraction, gene expression service |
is listed by: Eagle I is listed by: NIDDK Information Network (dkNET) has parent organization: Joslin Diabetes Center is organization facet of: Joslin Diabetes Center |
Diabetes | NIDDK P30DK036836 | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_156350 | SCR_009873 | 2026-02-14 02:07:36 | 590 | |||||||
|
Harvard Digestive Diseases Center Biomedical CORE B: Microscopy and Histopathology Resource Report Resource Website |
Harvard Digestive Diseases Center Biomedical CORE B: Microscopy and Histopathology (RRID:SCR_009836) | core facility, access service resource, service resource | Core facility that provides service for paraffin embedding, sectioning, staining, and frozen sectioning; shared equipment and service for confocal, widefield, photodocumentation, electron microscopy, and digital image processing; and an immunostaining service. | parrafin embedding, electron microscopy, immunostaining, digestive disease |
is listed by: Eagle I is listed by: NIDDK Information Network (dkNET) has parent organization: Harvard University; Cambridge; United States has parent organization: Harvard Digestive Disease Center is organization facet of: Harvard Digestive Disease Center |
digestive disease | NIDDK P30 DK034854 | Available to the research community | nlx_156305 | http://www.hms.harvard.edu/hddc/services/imaging/ChildrensHospitalBostonCoreB.htm | SCR_009836 | 2026-02-14 02:08:06 | 0 | ||||||
|
Penn Diabetes Research Center Radioimmunoassay and Biomarkers Core Facility Resource Report Resource Website |
Penn Diabetes Research Center Radioimmunoassay and Biomarkers Core Facility (RRID:SCR_010028) | core facility, access service resource, service resource | Core which offers high quality immunoassay services to basic, translational, and clinical investigators performing diabetes and related metabolic disease research. The core also provides consultation and training and education services. | assay service, diabetes research, immunoassay consultation |
is listed by: Eagle I is listed by: NIDDK Information Network (dkNET) has parent organization: University of Pennsylvania; Philadelphia; USA has parent organization: Penn Diabetes Research Center is organization facet of: Penn Diabetes Research Center |
Diabetes | NIDDK P30DK19525 | Restricted | nlx_156498 | SCR_010028 | Penn Diabetes Research Center Radioimmunoassay and Biomarkers Core | 2026-02-14 02:08:09 | 0 | ||||||
|
University of Pennsylvania Center for Molecular Therapy for Cystic Fibrosis Vector Core Facility Resource Report Resource Website 10+ mentions |
University of Pennsylvania Center for Molecular Therapy for Cystic Fibrosis Vector Core Facility (RRID:SCR_010038) | core facility, access service resource, service resource | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 30,2023. Core whose main aim is to provide vector technology for preclinical studies and other basic research applications. Its services include rovision of AAV, adenoviral and lentiviral based vectors, consultation and advice in the design of custom vectors and in vector serotype/pseudotype selection, and design, cloning and production of plasmid DNA for the production of custom vectors. | vector core, vector design, vector consultation, gene therapy program |
is listed by: Eagle I is listed by: NIDDK Information Network (dkNET) has parent organization: University of Pennsylvania; Philadelphia; USA has parent organization: University of Pennsylvania Center for Molecular Therapy for Cystic Fibrosis is organization facet of: Penn Diabetes Research Center is organization facet of: University of Pennsylvania Center for Molecular Therapy for Cystic Fibrosis |
Cystic Fibrosis | NIDDK P30 DK047757 | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_156509 | http://www.med.upenn.edu/gtp/vectorcore/ | SCR_010038 | University of Pennsylvania Center for Molecular Therapy for Cystic Fibrosis Vector Core | 2026-02-14 02:08:10 | 15 | |||||
|
Vanderbilt Diabetes Research and Training Center Hormone Assay and Analytical Services Core Facility Resource Report Resource Website |
Vanderbilt Diabetes Research and Training Center Hormone Assay and Analytical Services Core Facility (RRID:SCR_010181) | core facility, access service resource, service resource | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 30,2023. Core facility that supports diabetes, endocrine, and metabolic research across a range of species. Its objective is to provide sensitive, reproducible, and inexpensive analyses of hormones, amino acids, and other relevant chemicals. | diabetes, endocrine, hormone, metabolic, chemical analysis |
is listed by: Eagle I is listed by: NIDDK Information Network (dkNET) has parent organization: Vanderbilt University; Tennessee; USA has parent organization: Vanderbilt Diabetes Research and Training Center is organization facet of: Vanderbilt Diabetes Research and Training Center |
Diabetes | NIDDK DK059637; NIDDK DK020593 |
THIS RESOURCE IS NO LONGER IN SERVICE | nlx_156660 | SCR_010181 | , Vanderbilt Hormone Assay & Analytical Services Core, Vanderbilt Diabetes Research and Training Center Hormone Assay and Analytical Services Core | 2026-02-14 02:07:35 | 0 | ||||||
|
Vanderbilt Diabetes Research and Training Center Cell Imaging Shared Resource Core Facility Resource Report Resource Website |
Vanderbilt Diabetes Research and Training Center Cell Imaging Shared Resource Core Facility (RRID:SCR_010165) | core facility, access service resource, service resource, resource | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 30,2023. Core facility that provides any Vanderbilt researcher with access to imaging equipment and expert technical support for microscopy and analysis of tissue and cellular physiology. | diabetes, imaging equipment, microscopy, tissue analysis, cellular physiology |
is listed by: Eagle I is listed by: NIDDK Information Network (dkNET) has parent organization: Vanderbilt University; Tennessee; USA has parent organization: Vanderbilt Diabetes Research and Training Center is organization facet of: Vanderbilt Diabetes Research and Training Center |
Diabetes | NIDDK DK020593 | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_156644 | SCR_010165 | Vanderbilt Diabetes Research and Training Center Cell Imaging Shared Resource | 2026-02-14 02:08:17 | 0 | ||||||
|
Irritable Bowel Syndrome Outcome Study Resource Report Resource Website |
Irritable Bowel Syndrome Outcome Study (RRID:SCR_001504) | IBSOS | clinical trial, resource | Multi-center placebo-controlled randomized clinical trial to assess the short-term and long-term efficacy of cognitive behavior therapy (CBT) for irritable bowel syndrome (IBS) using two treatment delivery systems: self administered CBT and therapist administered CBT. Long term project goals are to develop an effective self-administered behavioral treatment program that can enhance the quality of patient care, improve clinical outcomes, and decrease the economic and personal costs of one of the most prevalent and intractable gastrointestinal disorders. | gastrointestinal disorder, cognitive behavior therapy, self-management, self-administered |
is listed by: NIDDK Information Network (dkNET) has parent organization: University at Buffalo; New York; USA |
Irritable bowel syndrome | NIDDK 5U01DK077738-07 | PMID:22846389 | Free | nlx_152839 | SCR_001504 | 2026-02-14 02:07:49 | 0 | |||||
|
Folic Acid for Vascular Outcome Reduction in Transplantation Resource Report Resource Website 1+ mentions |
Folic Acid for Vascular Outcome Reduction in Transplantation (RRID:SCR_001505) | FAVORIT | clinical trial, resource | Multi-center, randomized, double blind controlled clinical trial to determine whether treatment with a standard multivitamin augmented with high doses of folic acid, vitamin B6 and vitamin B12 reduces the rate of cardiovascular disease outcomes in renal transplant recipients relative to participants receiving a similar multivitamin that contains no folic acid. This study hopes to show that by reducing the level of homocysteine in the body, the risk of heart disease is also reduced among kidney transplant patients. | multivitamin, folic acid, vitamin b6, vitamin b12, outcome, homocysteine, adult human, middle adult human, late adult human, vitamin, bibliography |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) has parent organization: University of North Carolina at Chapel Hill; North Carolina; USA |
Cardiovascular disease, Kidney transplant recipient | NIDDK U01DK061700 | PMID:16923411 | Free, Freely available | nlx_152827 | http://www.cscc.unc.edu/favorit/ | http://www.cscc.unc.edu/favorit/favdescrip.htm | SCR_001505 | Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) | 2026-02-14 02:07:18 | 1 | ||
|
Family Investigation of Nephropathy of Diabetes Resource Report Resource Website |
Family Investigation of Nephropathy of Diabetes (RRID:SCR_001525) | FIND, F.I.N.D. | clinical trial, resource | Multicenter observational study designed to identify genetic determinants of diabetic nephropathy. It is conducted in eleven U.S. clinical centers and a coordinating center, and with four ethnic groups (European Americans, African Americans, Mexican Americans, and American Indians). Two strategies are used to localize susceptibility genes: a family-based linkage study and a case-control study using mapping by admixture linkage disequilibrium (MALD). In the family-based study, probands with diabetic nephropathy are recruited with their parents and selected siblings. Linkage analyses will be conducted to identify chromosomal regions containing genes that influence the development of diabetic nephropathy or related quantitative traits such as serum creatinine concentration, urinary albumin excretion, and plasma glucose concentrations. Regions showing evidence of linkage will be examined further with both genetic linkage and association studies to identify genes that influence diabetic nephropathy or related traits. Two types of MALD studies are being done. One is a case-control study of unrelated individuals of Mexican American heritage in which both cases and controls have diabetes, but only the case has nephropathy. The other is a case-control study of African American patients with nephropathy (cases) and their spouses (controls) unaffected by diabetes and nephropathy; offspring are genotyped when available to provide haplotype data. The specific goals of this program: * Delineate genomic regions associated with the development and progression of renal disease(s) * Evaluate whether there is a genetic link between diabetic nephropathy and diabetic retinopathy * Improve outcomes * Provide protection for people at risk and slow the progression of renal disease * Help establish a resource for genetic studies of kidney disease and diabetic complications by creating a repository of genetic samples and a database * Encourage studies of the genetics of progressive renal disease | genetic susceptibility, genetic pathway, renal, kidney, outcome, gene, genetics, european-american, african-american, mexican-american, american-indian, linkage association study, admixture linkage disequilibrium, mapping by admixture linkage disequilibrium, serum creatinine, urinary protein excretion, plasma glucose level, blood pressure, blood lipid level, trait, linkage, adult human, male, female, clinical |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
NIDDK 5R01DK053591 | PMID:15642484 | Free, Freely available | nlx_152825 | https://www.niddkrepository.org/studies/find/ | SCR_001525 | Family Investigation of Nephropathy and Diabetes (F.I.N.D.), Family Investigation of Nephropathy & Diabetes | 2026-02-14 02:07:49 | 0 | ||||
|
HALT PKD Resource Report Resource Website 1+ mentions |
HALT PKD (RRID:SCR_001529) | HALT PKD, HALT-PKD | clinical trial, resource | Consortium established to design and implement clinical trials of treatments that might slow the progressive loss of renal function in Polycystic Kidney Disease (PKD). Two multicenter randomized, double-blind, placebo controlled clinical trials are running concurrently to study the efficacy of renin-angiotensin-aldosterone system blockade on the progression of cystic disease (kidney volume) and on the decline in renal function in autosomal dominant polycystic kidney disease (ADPKD). Study A is to study whether intensive ACE-I/ARB blockade decrease the progression of cystic disease compared to ACE-I monotherapy patients with early disease, relatively preserved renal function, and high-normal BP or hypertension. Study B is to study whether intensive ACE-I/ARB blockade as compared to ACE-I monotherapy slow the decline in kidney function, end-stage of renal disease, or death in the setting of standard blood pressure control in hypertensive patients with moderately advanced disease. | treatment, renal function, lisinopril, placebo, telmisartan, male, female, adolescent, adult human |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: Washington University School of Medicine in St. Louis; Missouri; USA |
Polycystic kidney disease, Autosomal dominant polycystic kidney disease | NIDDK 5U01DK062408 | Free, Freely available | nlx_152832 | https://www.niddkrepository.org/studies/halt-pkd/ | http://www.pkd.wustl.edu/pkdtn/ | SCR_001529 | Polycystic Kidney Disease-Treatment Network | 2026-02-14 02:07:45 | 1 | |||
|
Clinical Islet Transplantation Study Resource Report Resource Website 1+ mentions |
Clinical Islet Transplantation Study (RRID:SCR_001515) | CIT Study | clinical trial, resource | Network of centers to conduct studies of islet transplantation in patients with type 1 diabetes to improve the safety and long-term success of methods for transplanting islets. It is the aim of this trial to improve methods of isolating islets, to improve techniques for the administering those transplanted islets; and to develop approaches to minimize the toxic effects of immunosuppressive drugs required for transplantation. | islet transplantation, islet, insulin, beta cell, pancreas, autoimmune, clinical | is listed by: NIDDK Information Network (dkNET) | Type 1 diabetes, Diabetes | NIDDK U01DK070431 | Free, Freely available | nlx_152840 | SCR_001515 | Clinical Islet Transplantation Trial, Islet Transplantation Trials for Type 1 Diabetes | 2026-02-14 02:07:27 | 4 | |||||
|
RiVuR Resource Report Resource Website 1+ mentions |
RiVuR (RRID:SCR_001539) | RIVUR | clinical trial, resource | Multicenter, randomized, double-blind, placebo-controlled trial is designed to determine whether daily antimicrobial prophylaxis is superior to placebo in preventing recurrence of urinary tract infection (UTI) in children with vesicoureteral reflux (VUR). The basic eligibility criteria are: (1) age at randomization of at least 2 months, but less than 6 years, (2) a diagnosed first febrile or symptomatic UTI within 42 days prior to randomization that was appropriately treated, and (3) presence of Grade I-IV VUR based on voiding cystourethrogram (VCUG). Patients will be randomly assigned to treatment for 2 years with daily antimicrobial prophylaxis (trimethoprim-sulfamethoxazole) or placebo. The study is designed to recruit 600 children (approximately 300 in each treatment group) over an 18-24 month period. The primary endpoint is recurrence of UTI. In addition, patients will be evaluated for secondary endpoints related to renal scarring and antimicrobial resistance. Scarring will be determined based on renal scintigraphy by 99mTc dimercaptosuccinic (DMSA) scan. Quality of life, compliance, safety parameters, utilization of health resources, and change in VUR will be assessed periodically throughout the study. | child, antimicrobial prophylaxis, placebo, antibiotic, renal scarring, pediatric, trimethoprim-sulfamethoxazole, intervention, kidney, antibiotic resistance, young human, infant, bibliography, clinical, trimethoprim, sulfamethoxazole |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: University of North Carolina at Chapel Hill; North Carolina; USA |
Vesico-ureteral reflux, Urinary tract infection | NIDDK | PMID:19570724 PMID:19018048 PMID:18076937 PMID:19018047 PMID:19086141 |
Free, Freely available | nlx_152848 | http://www.cscc.unc.edu/rivur/ | SCR_001539 | Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR), Randomized Intervention for Children with Vesicoureteral Reflux, Randomized Intervention for Vesicoureteral Reflux | 2026-02-14 02:07:49 | 1 | |||
|
National Gene Vector Biorepository Resource Report Resource Website 10+ mentions |
National Gene Vector Biorepository (RRID:SCR_004760) | NGVB | core facility, access service resource, service resource | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 11, 2023. Archiving services, insertional site analysis, pharmacology and toxicology resources, and reagent repository for academic investigators and others conducting gene therapy research. Databases and educational resources are open to everyone. Other services are limited to gene therapy investigators working in academic or other non-profit organizations. Stores reserve or back-up clinical grade vector and master cell banks. Maintains samples from any gene therapy related Pharmacology or Toxicology study that has been submitted to FDA by U.S. academic investigator that require storage under Good Laboratory Practices. For certain gene therapy clinical trials, FDA has required post-trial monitoring of patients, evaluating clinical samples for evidence of clonal expansion of cells. To help academic investigators comply with this FDA recommendation, the NGVB offers assistance with clonal analysis using LAM-PCR and LM-PCR technology. | gene therapy, clinical trial, testing, insertion site, gene, clinical, vector, cell line, pharmacology, toxicology, clonal analysis, FASEB list |
is related to: NIDDK Information Network (dkNET) is related to: Phoenix has parent organization: Indiana University School of Medicine; Indiana; USA is parent organization of: NGVB SeqMap Database is parent organization of: NGVB Toxicology Database |
NHLBI ; NCRR |
PMID:31910049 | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_76398 | http://www.ngvl.org/ https://www.ngvbcc.org/Home.action |
SCR_004760 | 2026-02-14 02:07:54 | 33 | |||||
|
Type 1 Diabetes Preclinical Testing Program Resource Report Resource Website |
Type 1 Diabetes Preclinical Testing Program (RRID:SCR_006861) | T1D-PTP, NIDDKT1D-PTP | service resource, resource | THIS RESOURCE IS NO LONGER IN SERVICE, documented August 22, 2016. Investigator access is provided to the established facilities and expertise needed to extend, enhance and validate preclinical studies of promising new therapeutics in cases where additional preclinical testing is needed to validate potential therapies under disease-specific conditions and in multiple animal models before therapeutics can enter the Type 1 Diabetes Rapid Access to Intervention Development (T1D-RAID) development pipeline. The T1D-RAID program provides resources for pre-clinical development of drugs, natural products, and biologics that will be tested as new therapeutics in type 1 diabetes clinical trials. The T1D-RAID program is not currently accepting applications. The T1D-PTP program currently supports two contracts, which are separate from each other and from the T1D-RAID NCI contract resources, to assist in preclinical development of therapeutics for T1D: * Agents to be tested for Preclinical Efficacy in Prevention or Reversal of Type 1 Diabetes in Rodent Models. Type 1 Diabetes Preclinical Testing Program (T1D-PTP) (NOT-DK-09-006) * Needs for Preclinical Efficacy Testing of Promising Agents to Prevent or Reverse Diabetic Complications (NOT-DK-09-009) The T1D-RAID and T1D-PTP are programs intended to remove the most common barriers to progress in identification and development of new therapies for Type 1 Diabetes. The common goal of these programs is to support and provide for the preclinical work necessary to obtain proof of principle establishing that a new molecule or novel approach will be a viable candidate for expanded clinical evaluation. | testing, therapeutic, clinical, drug, preclinical, therapy, drug development, high-throughput screening, animal model, formulation, pharmacology, toxicology |
is related to: Type 1 Diabetes - Rapid Access to Intervention Development is related to: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Type 1 diabetes, Diabetes | NIDDK | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_152741 | SCR_006861 | Type 1 Diabetes Preclinical Testing Program (T1D-PtP), NIDDKType 1 Diabetes Preclinical Testing Program | 2026-02-14 02:07:53 | 0 | |||||
|
Functional Dyspepsia Treatment Trial Resource Report Resource Website |
Functional Dyspepsia Treatment Trial (RRID:SCR_006691) | FDTT | clinical trial, resource | Multi-center, randomized, placebo-controlled trial evaluating the tricyclic antidepressant, amitriptyline and the selective serotonin reuptake inhibitor (SSRI), escitalopram to placebo in patients with functional dyspepsia. The purpose of this study is to determine whether amitriptyline and escitalopram are more efficacious than placebo in relief of the symptoms of functional dyspepsia, adjusting for psychological and psychiatric co-morbidities. | antidepressant, amitriptyline, selective serotonin reuptake inhibitor, escitalopram, placebo |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: ClinicalTrials.gov |
Functional dyspepsia | NIDDK | PMID:22343090 | nlx_152830 | SCR_006691 | Antidepressant Therapy for Functional Dyspepsia, Functional Dyspepsia Treatment Trial (FDTT) | 2026-02-14 02:07:23 | 0 | |||||
|
Maryland Genetics of Interstitial Cystitis Resource Report Resource Website |
Maryland Genetics of Interstitial Cystitis (RRID:SCR_006992) | MaGIC | clinical trial, resource | Clinical study that investigated several hundred families with two or more blood relatives with interstitial cystitis in order to understand the molecular genetic basis of this condition. The study sought to find changes in genes that are found far more commonly in family members who have interstitial cystitis than in those who do not have the disease. Identifying these genes should lead to a better understanding of the cause of interstitial cystitis. This is a national study which is conducted by telephone and mail, and in which participants could participate entirely from their home. | male, female, adolescent, adult human, genetics, risk factor, family history, bladder, pain, observational |
is related to: NIDDK Information Network (dkNET) has parent organization: ClinicalTrials.gov has parent organization: University of Maryland School of Medicine; Maryland; USA |
Interstitial cystitis | NIDDK | nlx_152843 | http://icresearch.umaryland.edu/magic.aspx | SCR_006992 | Maryland Genetics of Interstitial Cystitis (MaGIC) | 2026-02-14 02:07:53 | 0 | |||||
|
High-dose Ursodiol Therapy of Primary Sclerosing Cholangitis Resource Report Resource Website |
High-dose Ursodiol Therapy of Primary Sclerosing Cholangitis (RRID:SCR_006772) | HUSC | clinical trial, resource | Multi-center, placebo-controlled trial of ursodiol in primary sclerosing cholangitis (PSC). A total of 150 patients with previously untreated PSC without cirrhosis were randomly assigned to receive high doses of ursodiol (20-25 mg/kg/day) or placebo for two years. Patients underwent medical evaluation, endoscopic retrograde cholangiography, and liver biopsy before randomization and again at two-year intervals. The endpoints of therapy were progression of hepatic fibrosis, liver decompensation, liver transplantation, or death. The treatment phase of the study was stopped for futility in June 2008; however, patients continue to be followed. Ongoing mechanistic studies are underway. | treatment, placebo, ursodeoxycholic acid, intervention, randomized, adult human, male, female |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: ClinicalTrials.gov |
Primary Sclerosing Cholangitis | NIDDK | PMID:19585548 | nlx_152836 | SCR_006772 | Trial of High-dose Urso in Primary Sclerosing Cholangitis, High-dose Ursodiol Therapy of Primary Sclerosing Cholangitis (HUSC), Multicentered Randomized Trial of High-dose Urso in Primary Sclerosing Cholangitis | 2026-02-14 02:07:53 | 0 | |||||
|
Efficacy and Mechanisms of Glutamine Dipeptide in the Surgical Intensive Care Unit Resource Report Resource Website |
Efficacy and Mechanisms of Glutamine Dipeptide in the Surgical Intensive Care Unit (RRID:SCR_006806) | GLND | clinical trial, resource | Multi-center, double-blind, placebo-controlled, intent-to-treat Phase III trial, designed to determine the effect of parenteral glutamine (GLN) dipeptide on important clinical outcomes in patients requiring surgical intensive care unit (SICU) care and parenteral nutrition (PN) after cardiac, vascular, or intestinal surgery. Patients who required PN and SICU care will receive either standard glutamine (GLN)-free PN (STD-PN) or isocaloric, isonitrogenous alanyl-glutamine dipeptide (AG)-PN until enteral feedings are established. The study will determine whether AG-PN decreases hospital mortality, nosocomial infection and other important indices of morbidity and will obtain mechanistically relevant observational data in the subjects on whether AG-PN a) increases serial blood concentrations of glutathione (GSH), heat shock proteins (HSP)-70 and -27, and glutamine; b) decreases the serum presence of the bacterial products flagellin and lipopolysaccharide (LPS) and the adaptive immune response to these mediators; and c) improves key indices of innate and adaptive immunity. | parenteral nutrition, glutamine, glutamine dipeptide, clinical, outcome, adult human, mortality, nosocomial infection, immune cell function, hospital morbidity, morbidity, intensive care |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: Emory University; Georgia; USA |
Critical illness | NIDDK U01DK069322 | PMID:18596310 | nlx_152823 | http://www.sph.emory.edu/GLND | SCR_006806 | Phase III Study on the Efficacy of Glutamine Dipeptide-Supplemented Parenteral Nutrition in Surgical ICU Patients, Efficacy and Mechanisms of GLN Dipeptide in the SICU, Efficacy and Mechanisms of GLN Dipeptide in the SICU (GLND), GLND trial | 2026-02-14 02:07:23 | 0 | ||||
|
Diabetes Control and Complications Trial Resource Report Resource Website |
Diabetes Control and Complications Trial (RRID:SCR_006805) | DCCT | data or information resource, clinical trial, database, resource | Clinical study that showed that keeping blood glucose levels as close to normal as possible slows the onset and progression of eye, kidney, and nerve diseases caused by diabetes. EDIC is a follow-up study of people who participated in DCCT. The DCCT involved 1,441 volunteers, ages 13 to 39, with type 1 diabetes and 29 medical centers in the United States and Canada. Volunteers had to have had diabetes for at least 1 year but no longer than 15 years. They also were required to have no, or only early signs of, diabetic eye disease. The study compared the effects of standard control of blood glucose versus intensive control on the complications of diabetes. Intensive control meant keeping hemoglobin A1C levels as close as possible to the normal value of 6 percent or less. The A1C blood test reflects a person''''s average blood glucose over the last 2 to 3 months. Volunteers were randomly assigned to each treatment group. DCCT Study Findings * Intensive blood glucose control reduces risk of ** eye disease: 76% reduced risk ** kidney disease: 50% reduced risk ** nerve disease: 60% reduced risk When the DCCT ended, researchers continued to study more than 90 percent of participants. The follow-up study, called Epidemiology of Diabetes Interventions and Complications (EDIC), is assessing the incidence and predictors of cardiovascular disease events such as heart attack, stroke, or needed heart surgery, as well as diabetic complications related to the eye, kidney, and nerves. The EDIC study is also examining the impact of intensive control versus standard control on quality of life. Another objective is to look at the cost-effectiveness of intensive control. EDIC Study Findings * Intensive blood glucose control reduces risk of ** any cardiovascular disease event: 42% reduced risk ** nonfatal heart attack, stroke, or death from cardiovascular causes: 57% reduced risk | blood glucose, adolescent, young human, middle adult human, longitudinal, eye disease, kidney disease, nerve disease, cardiovascular disease, heart attack, stroke, blood pressure, blood lipid, complication |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Central Repository is related to: Epidemiology of Diabetes Interventions and Complications is related to: Epidemiology of Diabetes Interventions and Complications is related to: NIDDK Information Network (dkNET) has parent organization: National Diabetes Information Clearinghouse |
Type 1 diabetes, Diabetes | NIDDK | nlx_152798 | SCR_006805 | DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study | 2026-02-14 02:07:57 | 0 | ||||||
|
Frequent Hemodialysis Network Nocturnal Trial Resource Report Resource Website |
Frequent Hemodialysis Network Nocturnal Trial (RRID:SCR_007014) | FHN Nocturnal Trial | clinical trial, resource | Randomized controlled clinical trial where subjects will be randomized to conventional hemodialysis delivered three days per week home arm or to the six times per week nocturnal home hemodialysis arm which will follow any dialysis prescription provided their prescribed standardized Kt/V is at least 4.0 and treatment time is at least 6.0 hours, six times per week. Subjects were recruited from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 12 months. Primary Outcome Measures: * composite of 12 month mortality and the change over 12 months in left ventricular mass by cine-MRI, * a composite of 12 month mortality and the change over 12 months in the SF-36 RAND physical health composite Secondary Outcome Measures: * cardiovascular structure/funct (change in LV mass over 12 mos), health-related QoL/phys funct (change over 12 mos in PHC), * depression / dis burden (change over 12 mos in Beck Depression Inv.), nutrition (change over 12 mos in serum albumin, cognitive funct (change over 12 mos in TrailMaking Test B), mineral metabolism (change over 12 mos in aveg pre-dialysis serum phosphorus), * clin events (rate of non-access hospital or death * hypertension, anemia | hemodialysis, home, adult human, kidney, kidney disease |
is listed by: ClinicalTrials.gov is related to: Frequent Hemodialysis Network Daily Trial is related to: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
End Stage Renal Disease, Hemodialysis | NIDDK | PMID:21775973 PMID:17164834 PMID:17699439 |
nlx_152829 | SCR_007014 | Frequent Hemodialysis Network (FHN) Nocturnal Trial, Frequent Hemodialysis Network: Nocturnal Trial | 2026-02-14 02:07:23 | 0 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the FDI Lab - SciCrunch.org Resources search. From here you can search through a compilation of resources used by FDI Lab - SciCrunch.org and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that FDI Lab - SciCrunch.org has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on FDI Lab - SciCrunch.org then you can log in from here to get additional features in FDI Lab - SciCrunch.org such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into FDI Lab - SciCrunch.org you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
The SciCrunch Infrastructure was developed as a cooperative data platform to be used by diverse communities in making data more FAIR.
scicrunch.org
